CVS Health Says Company Will Reaffirm Its Previously Announced Full-year 2024 GAAP Diluted EPS Guidance Of At Least $7.26 And Full-year 2024 Adjusted EPS Guidance Of At Least $8.50 Vs. 8.59 Estimate
Portfolio Pulse from Benzinga Newsdesk
CVS Health will reaffirm its full-year 2024 earnings guidance, maintaining its GAAP diluted EPS at a minimum of $7.26 and its adjusted EPS at a minimum of $8.50, which is slightly below the estimated $8.59.
January 05, 2024 | 11:48 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
CVS Health reaffirms its 2024 GAAP diluted EPS guidance of at least $7.26 and adjusted EPS guidance of at least $8.50, marginally below the consensus estimate of $8.59.
Reaffirming guidance that is below analyst estimates can be perceived negatively by the market, potentially leading to short-term bearish sentiment. However, the impact may be moderated by the fact that the guidance was not reduced further, indicating stability in CVS Health's outlook.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100